Literature DB >> 35737914

Checkpoint Inhibitor Immunotherapy to Treat Temozolomide-Associated Hypermutation in Advanced Atypical Carcinoid Tumor of the Lung.

Fangdi Sun1, James P Grenert2, Lisa Tan1, Jessica Van Ziffle2, Nancy M Joseph2, Claire K Mulvey1, Emily Bergsland1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35737914      PMCID： PMC9249272          DOI： 10.1200/PO.22.00009

Source DB:  PubMed          Journal:  JCO Precis Oncol        ISSN： 2473-4284


× No keyword cloud information.
  46 in total

1.  Genetic, Epigenetic, and Immunologic Profiling of MMR-Deficient Relapsed Glioblastoma.

Authors:  Stefano Indraccolo; Giuseppe Lombardi; Matteo Fassan; Lorenza Pasqualini; Silvia Giunco; Raffaella Marcato; Alessandra Gasparini; Cinzia Candiotto; Silvia Nalio; Pasquale Fiduccia; Giuseppe Nicolò Fanelli; Ardi Pambuku; Alessandro Della Puppa; Domenico D'Avella; Laura Bonaldi; Marina Paola Gardiman; Roberta Bertorelle; Anita De Rossi; Vittorina Zagonel
Journal:  Clin Cancer Res       Date:  2018-12-04       Impact factor: 12.531

2.  Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study.

Authors:  Janice M Mehnert; Emily Bergsland; Bert H O'Neil; Armando Santoro; Jan H M Schellens; Roger B Cohen; Toshihiko Doi; Patrick A Ott; Michael J Pishvaian; Igor Puzanov; Kyaw L Aung; Chiun Hsu; Christophe Le Tourneau; Antoine Hollebecque; Elena Élez; Kenji Tamura; Marlena Gould; Ping Yang; Karen Stein; Sarina A Piha-Paul
Journal:  Cancer       Date:  2020-04-22       Impact factor: 6.860

3.  Typical and atypical carcinoid tumours: analysis of the experience of the Spanish Multi-centric Study of Neuroendocrine Tumours of the Lung.

Authors:  Mariano García-Yuste; José M Matilla; Antonio Cueto; José Manuel Rodríguez Paniagua; Guillermo Ramos; Miguel Angel Cañizares; Ignacio Muguruza
Journal:  Eur J Cardiothorac Surg       Date:  2006-12-29       Impact factor: 4.191

4.  Mismatch correction at O6-methylguanine residues in E. coli DNA.

Authors:  P Karran; M G Marinus
Journal:  Nature       Date:  1982-04-29       Impact factor: 49.962

5.  Impact of Therapy Sequence with Alkylating Agents and MGMT Status in Patients with Advanced Neuroendocrine Tumors.

Authors:  Sebastian Krug; Michael Boch; Peter Rexin; Thomas M Gress; Patrick Michl; Anja Rinke
Journal:  Anticancer Res       Date:  2017-05       Impact factor: 2.480

Review 6.  The role of DNA mismatch repair in drug resistance.

Authors:  D Fink; S Aebi; S B Howell
Journal:  Clin Cancer Res       Date:  1998-01       Impact factor: 12.531

Review 7.  A practical guide to biomarkers for the evaluation of colorectal cancer.

Authors:  Wei Chen; Wendy L Frankel
Journal:  Mod Pathol       Date:  2019-01-02       Impact factor: 7.842

8.  MGMT gene silencing and benefit from temozolomide in glioblastoma.

Authors:  Monika E Hegi; Annie-Claire Diserens; Thierry Gorlia; Marie-France Hamou; Nicolas de Tribolet; Michael Weller; Johan M Kros; Johannes A Hainfellner; Warren Mason; Luigi Mariani; Jacoline E C Bromberg; Peter Hau; René O Mirimanoff; J Gregory Cairncross; Robert C Janzer; Roger Stupp
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

9.  Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab.

Authors:  Andrew L Lin; Philip Jonsson; Viviane Tabar; T Jonathan Yang; John Cuaron; Katherine Beal; Marc Cohen; Michael Postow; Marc Rosenblum; Jinru Shia; Lisa M DeAngelis; Barry S Taylor; Robert J Young; Eliza B Geer
Journal:  J Clin Endocrinol Metab       Date:  2018-10-01       Impact factor: 5.958

10.  O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors.

Authors:  Matthew H Kulke; Jason L Hornick; Christine Frauenhoffer; Susanne Hooshmand; David P Ryan; Peter C Enzinger; Jeffrey A Meyerhardt; Jeffrey W Clark; Keith Stuart; Charles S Fuchs; Mark S Redston
Journal:  Clin Cancer Res       Date:  2009-01-01       Impact factor: 12.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.